An appraisal of recently patented compounds for bladder overactivity and urinary incontinence

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 7, 2004, Pages 1041-1060

  D'Agostino, Gianluigi ^a   Condino, Anna ^a   Gallinari, Paola ^a   Boselli, Cinzia ^a   Agazzi, Alessandro ^a   Tonini, Marcello ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Incontinence; Overactive bladder; Potential therapeutic agents; Urge incontinence

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMETIL; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BROMAZEPAM; CERIS; DARIFENACIN; DICYCLOVERINE; EMEPRONIUM BROMIDE; HYOSCYAMINE; LEXIL; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR; NEUROKININ 2 RECEPTOR ANTAGONIST; OXYBUTYNIN; POTASSIUM CHANNEL STIMULATING AGENT; PROPANTHELINE BROMIDE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; SOLIFENACIN; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST; TOLTERODINE; TRAMADOL; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URAPLEX; URINARY TRACT AGENT;

ADRENERGIC TRANSMISSION; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONSTIPATION; CONTROLLED DRUG RELEASE; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HYPOTENSION; MICTURITION REFLEX; NONHUMAN; OVERACTIVE BLADDER; PATENT; PATHOPHYSIOLOGY; PONS RETICULAR FORMATION; RAT; RECEPTOR BLOCKING; REVIEW; SEROTONINERGIC TRANSMISSION; URINE INCONTINENCE; VALIDATION PROCESS; XEROSTOMIA;

EID: 3543107217     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.7.1041     Document Type: Review

References (140)

1. TAKEDA M, ARAKI I, KAMIYAMA M, TAKIHANA Y, KOMURO M, FURUYA Y: Diagnosis and treatment of voiding symptoms. Urology (2003) 62(5.Suppl.2):11-19.
2. ABRAMS P, CARDOZO L, FALL M et al.: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol. Urodyn. (2002) 21:167-178.
3. MOSTWIN JL: Pathophysiology: the varieties of bladder overactivity. Urology (2002) 60(Suppl.5A):22-27.
4. WEIN AJ: Diagnosis and treatment of the overactive bladder. Urology (2003) 62(5.Suppl.2):20-27.
5. HUNSKAAS, LOSE G, SYKES D, VOSS S: The prevalence of UI in women in four European countries. Br. J. Urol. Int. (2004) 93:324-330.
6. MINASSIAN VA, DRUTZ HP, AL-BADR A: UI as a worldwide problem. Int. J. Gynaecol. Obstet. (2003) 82(3):327-338.
7. ABRAMS P: Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology (2003) 62(Suppl.5B):28-37.
8. STEWART WF, VAN ROOYEN JB, CUNDIFF GW et al.: Prevalence and burden of overactive bladder in the United States. World J. Urol. (2003) 20:327-336.
9. MOLLER LA, LOSE G, JORGENSEN T: The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age. Acta Obstet. Gynecol. Scand. (2000) 79(4):298-305.
10. UEDA T, TAMAKI M, KAGEYAMA S, YOSHIMURA N, YOSHIDA O: UI among community-dwelling people aged 40 years or older in Japan: prevalence, risk factors, knowledge and self-perception. Int. J. Urol. (2000) 7(3):95-103.
11. THOM D: Variation in estimates of UI prevalence in the community: effects of differences in definition, population characteristics, and study type. J. Am. Geriatr. Soc. (1998) 46(4):473-480.
12. HUNSKAARS, BURGIO K, DIOKNO A, HERZOG AR, HJALMAS K, LAPITAN MC: Epidemiology and natural history of UI in women. Urology (2003) 62(Suppl.4A):16-23.
13. MILSOM I, ABRAMS P, CARDOZO L, ROBERTS RG, THUROFF J, WEIN AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br. J. Urol. Int. (2001) 87:760-766.
14. HAY-SMITH J, HERBISON P, ELLIS G, MOORE K: Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Library (2004): 1. (Cochrane Review).
15. HERBISON P, HAY-SMITH J, ELLIS G, MOORE K: Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br. Med. J. (2003) 326:1-7.
16. ANDERSSON KE, YOSHIDA M: Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur. Urol. (2003) 43(1):1-5.
17. BRADING AF: The physiology of the mammalian urinary outflow tract. Exp. Physiol. (1999) 84(1):215-221.
18. VAUGHAN CW, SATCHELL PM: Urine storage mechanisms. Progr. Neurobiol. (1994) 46:215-237.
19. DE GROAT WC, YOSHIMURA N: Pharmacology of the lower urinary tract. Ann. Rev. Pharmacal. Toxicol. (2001) 41:691-721.
20. GABELLA G, DAVIS C: Distribution of afferent axons in the bladder of rats. J. Neurocytol. (1998) 27(3):141-155.
21. HEDGE SS, EGLEN RM: Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci. (1999) 64:419-442.
22. 4 receptor subtype. Br. J. Pharmacol. (2000) 129(3):493-500.
23. 3-receptors mediate contraction of human detrusor muscle in vitro. J. Auton. Pharmacol. (2001) 21:243-248.
24. 3 muscarinic receptors mediate contraction of human urinary bladder. Br. J. Pharmacol. (2002) 136(5):641-643.
25. CAUFIELD MP, BIRDSALL NJ: International Union of Pharmacology XVII: classification of muscarinic acetylcholine receptors. Pharmacol. Rev. (1998) 50(2):279-290.
26. SIGALA S, MIRABELLA G, PERONI A et al.: Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology (2002) 60:719-725.
27. YAMAGUCHI O, SHISHIDO K, TAMURA K et al.: Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J. Urol. (1996) 156:1208-1213.
28. EGLEN RM, CHOPPIN A, WATSON N: Therapeutic opportunities from muscarinic receptor research. Trends Pharmocol. Sci. (2001) 22(8):409-414.
29. 3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br. J. Pharmacol. (1997) 120(8):1409-1418.
30. DANIELS DV, MELOY TD, LOURY DN et al.: Functional pharmacological characterization of the muscarinic cholinoceptor-mediated inhibition of adenylyl cyclase in primary cultured human bladder detrusor smooth muscle cells. Life Sci. (1999) 64:590.
31. SOMOGYI GT, DE GROAT WC: Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci. (1999) 64(6-7):411-418.
32. 3H-acetylcholine secretions in the guinea pig urinary bladder in vitro. J. Pharmocal. Exp. Ther. (1995) 274:1458-1468.
33. 3H]acetylcholine release in the rat isolated urinary bladder. J. Pharmacol. Exp. Ther. (1997) 283(2):750-756.
34. 1-Adrenergic receptor regulation: basic science and clinical implications. Pharmacol. Ther. (2000) 88(3):281-309.
35. GOEPEL M, WITTMANN A, RUBBEN H, MICHEL M: Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate. Urol. Res. (1997) 25(3):199-206.
36. 1-adrenoceptors in the aetiology of LUTS. Eur. Urol. Suppl. (2002) 1:5-13.
37. 1-Adrenergic receptor subtypes in human detrusor. J. Urol. (1998) 160(3):937-943.
38. 1-adrenoceptors in the rat urinary bladder. Br. J. Pharmacol. (1995) 114:1710-1716.
39. 2-adrenoceptors on bladder activity induced by bladder distension in anaesthetised rat. Br. J. Urol. Int. (2000) 85(7 ):925-931.
40. 3-adrenoceptor subtypes in relaxation of the urinary bladder detrusor: analysis by molecular biological and Pharmacological methods. J. Pharmacol. Exp. Ther. (1999) 288:1367-1373.
41. ANDERSSON KE: Pharmacology of the lower urinary tract smooth muscle and penile erectile tissues. Pharmacol. Rev. (1993) 45:253-230.
42. 3-Adrenoceptors in human detrusor muscle. Urology (2002) 59(Suppl. 5A):25-29.
43. 3 adrenoceptor in the human detrusor muscle. Br. J. Pharmacol. (1999) 126:819-825.
44. RAYMOND JR, MUKHIN YV, GELASCO A et al.: Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol. Ther. (2001) 92(2-3):179-212.
45. TONINI M, MESSORI E, FRANCESCHETTI GP et al.: Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. Br. J. Pharmacol. (1994) 113(1):1-2.
46. 4 receptors enhance tritiated acetylcholine release from electrically-stimulated human detrusor strips. Pharmacol. Res. (2001) 43(Suppl. A):124.
47. SEVERINI C, IMPROTA G, FALCONIERI-ERSPAMER G, SALVADORI S, ERSPAMER V: The tachykinin peptide family. Pharmacol. Rev. (2002) 54(2):285-322.
48. BURCHER E, ZENG XP, STRIGAS J, SHANG F, MELLARD RJ, MOORE KH: Autoradiographic localisation of tachykinin and calcitonin gene-related peptide receptors in adult urinary bladder. J. Urol. (2000) 163(1):331-337.
49. SMET PJ, MOORE KH, JONAVICIUS J: Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab. Invest. (1997) 77(1):37-49.
50. BOSELLI C, GOVONI S, CONDINO AM, D'AGOSTINO G: Bladder instability: a re-appraisal of classical experimental approaches and development of new therapeutic strategies. J. Auton. Pharmacol. (2001) 21(5-6):219-229.
51. NORTH RA: Molecular physiology of P2X receptors. Physiol. Rev. (2002) 82:1013-1067.
52. DUNN PM, ZHONG Y, BURNSTOCK G: P2X receptors in peripheral neurons. Prog. Neurobiol. (2001) 65:107-134.
53. MOORE KH, RAY RR, BARDEN JA: Loss of purinergic P2X3 and P2X5 receptor innervation in human detrusor from adults with urge incontinence. J. Neurosci. (2001) 21(RC166):1-6.
54. O'REILLY BA, KOSAKA AH, CHANG TK, FORD AP, POPERT R, MCMAHON SB: A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. Br. J. Urol. Int. (2001) 87(7):617-622.
55. JAGGAR JH, PORTER VA, LEDERER VJ, NELSON MT: Calcium sparks in smooth muscle. Am. J. Physiol. Cell. Physiol. (2000) 278:C235-C256.
56. SEINO S: ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Ann. Rev. Physiol. (1999) 61:337-362.
57. + channels. Ann. NY Acad. Sci. (1999) 868:233-285.
58. SHIEH CC, COGHLAN M, SULLIVAN JP: Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol. Rev. (2000) 52:557-594.
59. COGHLAN MJ, CARROLL WA, GOPALAKRISHNAN M: Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J. Med. Chem. (2001) 44(11):1627-1653.
60. + channels in the pig and human detrusor. Eur. J. Pharmacol. (2000) 400(2-3):287-295.
61. + channels and gap junctions in urogenital smooth muscle: implications for improved understanding of urogenital function, disease and therapy. Curr. Drug Targets (2001) 2(1):1-20.
62. BUCKNER SA, MILICIC I, DAZA AV, COGHLAN WJ, GOPALAKRISHNAN M: Spontaneous phasic activity of the pig urinary bladder smooth muscle: characteristics and sensitivity to potassium channel modulators. Br. J. Pharmacol. (2002) 135(3):639-648.
63. BLOK BFM, WILLEMSEN AT, HOLSTEGE G: A PET study on brain control of micturition in humans. Brain (1997) 120:111-121.
64. YAN Z: Regulation of GABAergic inhibition by serotonin signaling in prefrontal cortex: molecular mechanisms and functional implications. Mol. Neurobiol. (2002) 26(2-3):203-216.
65. 1-adrenergic receptor subtypes at four distinct levels. Mol. Brain Res. (1999) 63(2 ):254-261.
66. 2-Adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding α2-adrenergic receptor subtypes at four distinct levels. Brain Res. Mol. Brain Res. (1995) 34(1):109-111.
67. 2-receptor agonists on urinary bladder contraction in conscious rats. Jpn. J. Pharmacol. (2000) 84(4):381-390.
68. 1-adrenoceptors. Br. J. Pharmacol. (1996) 117:962-966.
69. ESPEY MJ, DU HJ, DOWNIE JW: Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats. Brain Res. (1998) 798(1-2):101-108.
70. BURGARD EC, FRASER MO, THOR KB: Serotonergic modulation of bladder afferent pathways. Urology (2003) 62(Suppl. 4A):10-15.
71. DE GROAT WC: Influence of central serotonergic mechanisms on lower urinary tract function. Urology (2002) 59(5.Suppl. 1):30-36.
72. GOBERT A, LEJEUNE F, RIVET JM, AUDINOT V, NEWMAN-TANCREDI A, MILLAN MJ: Modulation of the activity of central serotoninergic neurons by novel serotonin 1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats. J. Pharmacol. Exp. Ther. (1995) 273(3):1032-1046.
73. HELTON L, THOR KB, BAEZ M: 5-Hydroxytryptamine 2A, 5-hydroxytryptamine 2B and 5-hydroxytryptamine 2C receptor mRNA expression in the spinal cord of rat, cat, monkey, and human. Neuroreport (1995) 5:2617-2620.
74. ANDREE B, HEDMAN A, THORBERG SO, NILSSON D, HALLDIN C, FARDE L: Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain. Psychopharmacology (2003) 167(1):37-45.
75. 1C/2 binding sites in the rat spinal cord. Neuroscience (1993) 55:235-252.
76. 2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cat. Br. J. Pharmacol. (1996) 118(1):150-154.
77. 3 receptors in the rat central nervous system are mainly located on nerve fibres and terminals. Brain Res. (1993) 612:289-293.
78. 1A-receptor antagonist on the micturition-reflex pathway in the rat. Am. J. Physiol. (2001) 280:R1407-R1413.
79. 3 recptors are involved in dorsal root reflexes: possible role in periaqueductal gray descending inhibition. J. Neurophysiol. (2001) 86(1):49-58.
80. CHAIKIN DC, BLAIVAS JG: Voiding dysfunction: definitions. Curr. Opin. Urol. (2001) 11:395-398.
81. SCHUMACHER S: When is a urodynamic investigation indicated for overactive bladder? Urologe A. (2003) 42(6):801-806.
82. BRADING AF: A myogenic basis for the overacting bladder. Urology (1997) 50(Suppl.6A):57-69.
83. DE GROAT WC: A neurologic basis for me overactive bladder. Urology (1997) 50(Suppl.6A):36-52.
84. YOSHIDA M, HOMMA Y, INADOME A et al.: Age-related changes in cholinergic and purinergic neurotransmission in human isolated bladder smooth muscles. Exp. Gerontol. (2001) 36(1):99-109.
85. HARRISON SC, HUNNAM GR, FARMAN P, FERGUSON DR, DOYLE PT: Bladder instability and denervation in patients with bladder outflow obstruction. Br. J. Urol. (1987) 60(6):519-522.
86. MILLS IW, GEENLAND JE, MCMURRAY G et al.: Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J. Urol. (2000) 163(2):646-651.
87. FRY CH, SKENNERTON D, WOOD D, WU C: The cellular basis of contraction in human detrusor smooth muscle from patients with stable and unstable bladders. Urology (2002) 59(5Suppl.1):3-12.
88. 2 muscarinic receptor mediates in-vitro bladder contractions from patients with neurogenic bladder dysfunction. Am. J. Physiol. Regul. Integr. Comp. Physiol. E-pub (29/01/2004).
89. CHESS-WILLIAMS R: Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton. Autacoid. Pharmacol. (2002) 22(3):133-145.
90. SERELS S, STEIN M: Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. Neurourol. Urodyn. (1998) 17(1):31-36.
91. BLUE DR, DANIELS DV, GEVER JR et al.: Pharmacological characteristics of Ro115-1240, a selective α1A/1L-adrenoceptor partial agonist: a potential therapy for stress UI. Br. J. Urol. Int. (2004) 93(1):162-170.
92. LEPOR H. THEUNE C: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. J. Urol. (1995) 154(1):116-118.
93. BUZELIN JM, FONTEYNE E, KONTTURI M, WITJES WP, KHAN A: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br. J. Urol. (1997) 80(4):597-605.
94. LEPOR H: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology (1998) 51(6):892-900.
95. SULLIVAN J, ABRAMS P: α-Adrenoceptor antagonists in neurogenic lower urinary tract dysfunction. Urology (1999) 53(3.Suppl.3a):21-27.
96. KAKIZAKI H, KOYANAGI T: Current view and status of the treatment of lower urinary tract symptoms and neurogenic lower urinary tract dysfunction. Br. J. Urol. Int. (2000) 85(Suppl.2):25-30.
97. 1-adrenoreceptor antagonists. Br. J. Urol. Int. (2000) 85(Suppl.2):1-5.
98. 1-adrenoceptors. Eur. J. Pharmacol. (2001) 414(1 ):31-35.
99. 1-adrenergic receptor subtype expression by bladder outlet obstruction. J. Urol. (2002) 167(3):1513-1521.
100. 1D subtype in filling symptoms and effects of ageing on vascular expression. Br. J. Urol. Int. (2000) 85(Suppl.2):6-11.
101. LECCI A, GIULIANI S, MEINI S, MAGGI CA: Nociceptin and the micturition reflex. Peptides (2000) 21(7):1007-1021.
102. LECCI A, MAGGI CA: Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system. Regul. Pept. (2001) 101(1-3):1-18.
103. IGAWA Y, SATOH T, MIZUSAWA H et al.: The role of capsaicin-sensitive afferents in autonomic dysreflexia in patients with spinal cord injury. Br. J. Urol. Int. (2003) 91(7):637-641.
104. MOORE KH, LAM DS, LYNCH W: The tachykinin NK-2 receptor antagonist SR48968 does not block noncholinergic contractions in unstable human bladder. Peptides (2002) 23(6):1155-1160.
105. RAY FR, MOORE KH, HANSEN MA, BARDEN JA: Loss of purinergic P2X receptor innervation in human detrusor and subepithelium from adults with sensory urgency. Cell Tissue Res. (2003) 314(3):351-359.
106. DUTTON JL, HANSEN MA, BALCAR VJ, BARDEN JA. BENNETT MR: Development of P2X receptor dusters on smooth muscle cells in relation to nerve varicosities in the rat urinary bladder. J. Neurocytol. (1999) 28(1):4-16.
107. TAGLIANI M, CANDURA SM, DI NUCCI A et al.: A re-appraisal of the nature of the atropine-resistant contraction to electrical field stimulation in the human isolated detrusor muscle. Naunyn Schmiedebergs Arch. Pharmacol. (1997) 356(6):750-755.
108. BAYLISS M, WU C, NEWGREEN D, MUNDY ADRENOCEPTOR, FRY CH: A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. J. Urol. (1999) 162:1833-1839.
109. 1 purinoreceptor in human bladder. Exp. Physiol. (2000) 85(4):461-463.
110. ANDERSSON KE, HEDLUND P: Pharmacologic perspective on the physiology of the lower urinary tract. Urology (2002) 60(5.Suppl. 1): 13-20.
111. GUAY DR: Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin. Pharmacokinet. (2003) 42(14):1243-1285.
112. HILLS CJ, WINTER SA, BALFOUR JA: Tolterodine. Drugs (1998) 55(6):813-820.
113. NILVEBRANT L: Clinical experiences with tolterodine. Life Sci. (2001) 68(22-23):2549-2556.
114. MALONE-LEE JG, WALSH JB, MAUGOURD MF: Tolterodine: a safe and effective treatment for older patients with overactive bladder. J. Am. Geriatr. Soc. (2001) 49(6):700-705.
115. GARELY AD, BURROWS LJ: Current pharmacotherapeutic strategies for overactive bladder. Expert Opin. Pharmacother. (2002) 3(7):827-833.
116. DMOCHOWSKI RR, APPELL RA: Advancements in pharmacologic management of the overactive bladder. Urology (2000) 56(Suppl.6A):41-49.
117. ROVNER ES, WEIN AJ: Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur. Urol. (2002) 41(1):6-14.
118. GUPTA S, SATHYAN G, MORI T: New perspectives on the overactive bladder pharmacokinetics and bioavailability. Urology (2002) 60(5.Suppl.1):78-80.
119. DIOKNO AC, APPELL RA, SAND PK et al.: Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutymin and tolterodine for overactive bladder: results of the OPERA trial. Mayo. Clin. Proc. (2003) 78(6):687-695.
120. FUSGEN I, HAURI D: Trospium, chloride: an effective option for medical treatment of bladder overactivity. Int. J. Clin. Pharmacol. Ther. (2000) 38(5):223-234.
121. LOPEZ PEREIRA P, MIGUELEZ C, CAFFARATI J, ESTORNELL F, ANGUERA A: Trospium chloride for the treatment of detrusor instability in children. J. Urol. (2003) 170(5):1978-1981.
122. HALASKA M, RALPH G, WIEDEMANN A et al.: Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J. Urol. (2003) 20(6):392-399.
123. PAK RW, PETROU SP, STASKIN DR: Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr. Urol. Rep. (2003) 4(6):436-440.
124. 3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch. Pharmacol. (2002) 366(2):97-103.
125. HATANAKA T, UKAI M, OHTAKE A et al.: In vitro tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats and monkeys. International Continence Society Meeting, Florence, Italy (2003). (Abstract 312).
126. 2+ mobilization study in monkey cells. Life Sci. (2004) 74(7):843-853.
127. CHAPPLE CR, RECHBERGER T, AL-SHUKRI S: Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Br. J. Urol. Int. (2004) 93(3):303-310.
128. MIYAMAE K, YOSHIDA M, MURAKAMI S et al.: Pharmacological effects of darifenacin on human isolated urinary bladder. Pharmacology (2003) 69(4):205-211.
129. CARDOZO L, PRESCOTT K, SERDAREVIC D, SKILLERN L: Can medication prolong warning time? Proceeding International Contincence Saciety Meeting, Florence, Italy (2003).
130. KERBUSCH T, MILLIGAN PA, KARLSSON MO: Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. Br. J. Clin. Pharmacol. (2004) 57(2):170-180.
131. TESTA R, GUARNERI L, ANGELICO P et al.: Effect of different 5-hydroxytryptamine receptor subtype antagonists on the micturition reflex in rats. Br. J. Urol. Int. (2001) 87(3):256-264.
132. 1A receptor antagonist, on bladder function in rats. Naunyn Schmiedebergs Arch. Pharmacol. (2002) 366(6):528-536.
133. KHALED SM, ELHILALI M: Role of 5-HT receptors in treament of overactive bladder. Drugs Today (2003) 39(8):599-607.
134. MILLARD RJ, MOORE K, RENCKEN R, YALCIN I, BUMP RC: Duloxetine versus placebo in the treatment of UI: a four-continent randomized clinical trial. Br. J. Urol. Int. (2004) 93(3):311-318.
135. 7 receptors in the micturition reflex in anaesthetized female rats. Br. J. Pharmacol. (2003) 140(1):53-60.
136. ISHIZUKA O, GU B, IGAWA Y, NISHIZAWA O, PEHRSON R, ANDERSSON KE: Role of supraspinal serotonin receptors for micturition in normal conscious rats. Neurourol. Urodyn. (2002) 21(3):225-230.
137. MESSORI E, RIZZI CA, CANDURA SM, LUCCHELLI A, BALESTRA B, TONINI M: 5-Hydroxytryptamine receptors that facilitate excitatory neuromuscular transmission in the guinea-pig isolated detrusor muscle. Br. J. Pharmacol. (1995) 115(4):677-683.
138. CHAPPLE CR, RADLEY SC, MARTIN SW, SELLERS DJ, CHESS-WILLIAMS R: Serotonin-induced potentiation of cholinergic responses to electrical field stimulation in normal and neurogenic overactive human detrusor muscle. Br. J. Urol. Int. (2004) 93(4):599-604.
139. WEIN AJ: Pharmacological agents for the treatment of UI due to overactive bladder. Expert Opin. Investig. Drugs (2001) 10(1):65-83.
140. MICHEL MC, BRIONI JD: Meeting report for the ASPET Ray Fuller Symposium: lower urinary tract disorders: physiology, pharmacology, and therapeutic approaches. J. Pharmacol. Exp. Ther. (2002) 303(1):431-437.